Compared to histamine-2 receptor antagonists (H2RAs), new users of proton pump inhibitors (PPIs) are at increased risk of gastric cancer after five years of follow-up, according to an article published in Gut .
This observational population-based cohort study analysed 973,281 new users of PPIs and 193,306 new users of H2RAs to...